Automatization of Immunohistochemistry Data Analysis for Protocol Validation
This presentation was given by Marie Gerus-Durand, Principal Scientist & Validation Engineer at Cerba Research Montpellier at the JMP Discovery Summit Europe.
Cerba Research is a global company providing high-quality, specialized analytical and diagnostic solutions for clinical trials. Cerba Research Montpellier develops customized immunohistochemistry protocols to detect the expression of selected targets on patients’ tissue sections.
To be used in clinical trials, these protocols must meet the regulatory agencies’ criteria to ensure that the protocol will allow consistent results on precious patients’ samples. With the diversity of parameters evaluated and the types of evaluation possible in implementing these custom protocols, automating data analysis became a need.
Thanks to various JMP® tools, we have developed an automated analysis that saves time and homogenizes protocol performance reports by including statistical and graphical data in a Dashboard. This process, submitted as JMP Add-in, has been incorporated into our user workflows, thus facilitating our procedures.
Learn how Cerba Research and Fulgent are enhancing genomic data in clinical trials for better patient outcomes across all phases through their NGS services. In this presentation, you’ll learn how we’re accelerating precision medicine with next generation biomarker discovery through our partnership and specific expertise in oncology, rare disease, CNS, metabolic, and infectious diseases.
Discover the art of histopathology through the eyes of our most skilled scientists.
Immunohistochemistry biomarkers are key players in clinical development success. Tissue biomarkers can aid in the confirmation of diagnosis, patient selection, and/or for mechanistic evaluation.
If you would like to know more about how Cerba Research can help you, our IHC expert scientific team will consult with you on your specific needs. Flexible in our approach and delivery to provide timely and cost effective solutions to meet your clinical and commercial objectives.
Download our digital book to see the art of histopathology for yourself.
Advantages and Versatility of Flow Cytometry Considerations for Clinical trial Speciality Lab Outsourcing
It is now clear that the therapeutic future lies in biomarkers through the development of immunotherapies and companion diagnostics. Among the techniques of biomarker analysis, there is Flowcytometry, which allows for precise analysis of liquid samples, but not only.
Validation test development for specific biomarkers is a prerequisite for a successful application in translational research, preclinical and clinical phases. The advantages and disadvantages of this technique, the samples, the conditions of use: Cerba Research will open the doors of its worldwide laboratories for an hour. To answer all your questions about one of the leading techniques of analysis for the development of innovative treatments, our experts will share their knowledge and experience.
Learning Objectives
What is Flow Cytometry?
What is the benefit of this technique?
How is it implemented in clinical trials?
Assays management details
Speakers
Nithianandan Selliah, Ph.D., Global Head of Flow Cytometry at Cerba Research
Nithianandan obtained his PhD in Immunology and started to work on HIV research. After more than 10 years of HIV research, he joined a biotech company to work on biomarker discovery for autoimmune diseases. His interest in Flow cytometry at the biotech company lead him to join global CRO to work on assay development and validation in Flow cytometry for global clinical trials. He joined Cerba Research to continue to work on his passion of Flow cytometry in clinical trial and takes on new challenges to build the best Flow cytometry service to the clients.
He is working with exceptional scientific teams in US and Belgium to bring on new assays for various therapeutic indications, including Immuno-oncology and autoimmune diseases.
Ishita Modi, Director, Scientific Customer Solutions at Cerba Research
A microbiologist by education, Ishita finished her studies from Gujarat University in India, and moved on to starting her career in United States. She has more than 15 years of experience in clinical and diagnostic research industry. Her expertise is in building a strong foundation of clinical operations and clinical research with commitment to meeting client’s scientific needs to help advance medicine. Ishita has worked at CRO/Central Lab as well as at some of the leading clinical diagnostic labs in the region. Her scientific expertise includes infectious diseases and genetics, and gained extensive experience in microbiology, virology and molecular biology. Ishita is a New York State certified Medical Technologist and also certified IRB (Institutional Review Board) professional. Her experience over the years has made her very strong in all aspects of clinical research and regulatory requirements. She has a passion for advancing science and making a difference in the future of healthcare.
Webinar – Advantages and Versatility of Flow Cytometry Considerations for Clinical trial Speciality Lab Outsourcing
Reach out to our experts to see how we can help advance your clinical trial
The Value of Biomarkers from Discovery to Commercialization
Why do some patients respond to therapy while others do not? The answer can be found in the concept of biomarkers: objective, measurable indicators of the presence or severity of disease. Used for decades to aid medical diagnosis, researchers today use biomarkers in every phase of drug discovery and development. There’s good reason. Biomarkers can triple drug development success rates, accelerating the availability of new therapeutics.
Download our article by Jérôme Sallette, CSO at Cerba Research, to learn more on the advantages of biomarkers in clinical research.
Article – The Value of Biomarkers From Discovery Through Commercialization
Skip to content
Resource Library
